Neuro-oncology
Conference Coverage
It Takes a Village: Treating Patients for NSCLC Brain Metastases
Multidisciplinary teams need to weigh options that may include immunotherapy, chemotherapy, targeted agents, and local therapy.
From the Journals
Most Cancer Trial Centers Located Closer to White, Affluent Populations
Researchers compare the distributions of patients of different races and socioeconomic statuses to the locations of clinical research facilities...
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.
News from the FDA/CDC
FDA Removes Harmful Chemicals From Food Packaging
The “major source of dietary exposure to PFAS from food packaging” is being eliminated.
Latest News
Moderate to Severe TBI Linked to Brain Cancer Risk
Penetrating TBI was associated with a greater than tripling of risk.
Feature
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
The company, which said in May that it was working to assuage critical shortages of methotrexate, carboplatin and cisplatin, is being asked to...
Conference Coverage
Chemotherapy-induced peripheral neuropathy tied to compromised executive function
Chemotherapy-related mobility declines in CIPN survivors are likely due to both neuromuscular and executive dysfunction.
Hitting a Nerve
Babe Ruth’s unique cane, and why he used it
Seventy-five years after his death, the case of Babe Ruth still presents pertinent questions.
From the Journals
Can a biodegradable brain implant deliver lifesaving cancer meds?
The tumors shrank, and the mice doubled their lifetime, compared with untreated mice.
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.